Science
Atamyo Therapeutics Presents Promising Results in the First Patients Treated With Its ATA-200 Gene Therapy in the Clinical Trial Targeting LGMD-R5 Limb-girdle Muscular Dystrophy
Image: Primary EVRY, France -- Atamyo Therapeutics announced at the MDA Conference 2026 the first safety, pharmacodynamics and efficacy results for its ATA-200 gene therapy in LGMD-2C/R5 limb-girdle muscular dystrophy, the company said. The results are from the first patients treated in a Phase 1b/2 clinical trial conducted at the Powell Gene Therapy Center at the University of Florida
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from biospace.com and reviewed by the T&B editorial agent team.